The Cancer Nanotechnology (CN) Program Area was formed in 2011 upon the strong advice of our EAB. CN Program Area aims are to: 1) engineer, test and deliver therapeutic anti-cancer nanoparticles; 2) develop nanoscale imaging and mechanics to detect, quantify and track cancers; 3) invent and refine surface, analytic and manipulative nanoscale platforms; and 4) integrate systems biology and translate promising approaches into preclinical and early phase clinical testing. The Program Area is led by Michael Teitell, MD, PhD (UCLA) and James Heath, PhD (Caltech). UCLA and Caltech have several longstanding, beneficial collaborations, including a combined Medical Scientist Training Program (MSTP), a Joint Center for ? Translational Medicine (JCTM) and an NCI-funded Center of Cancer Nanotechnology Excellence (CCNE). The CN Program Area combines the strengths of these two leading institutions to facilitate the translation of discoveries in nanotechnology into advances against cancer. As with other Program Areas, the JCCC fosters numerous interactions and many of the JCCC's Shared Resources support investigators in the CN Program Area. The CN Program Area is comprised of 26 members, including four
Advances in nanotechnology hold great promise for the treatment and diagnosis of cancer. The Cancer Nanotechnology Program Area plays an important role in the realization of this promise by bringing nanotechnology researchers together with cancer biologists and physicians. By promoting interactions between these diverse groups, by supporting valuable shared resources and by funding innovative and collaborative research directions, it is anticipated that important new technologies and clinical advances will continue to emerge.
Showing the most recent 10 out of 767 publications
